AZN— AI Stock Forecast & Price Targets
Published 7/16/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live AZN price forecast →
AstraZeneca has sold off ~17% in the past quarter to $168, driven by the Wainua/eplontersen amyloidosis trial setback, dragging the stock below all key moving averages into oversold territory (RSI 38) ahead of the July 27 earnings print. Fundamentals remain solid — 10% TTM sales growth, 28% operating margins, 23% ROE, and a fresh $1.5B Zegfrovy lung-cancer in-licensing deal from Dizal — but the near-term setup is a binary earnings event against a weak tape. I lean constructive at these levels but wait for the print; a pre-earnings starter with room to add below is the right posture.
Earnings on July 27 (~11 days out) is a binary catalyst — do NOT size a full position pre-print. A small starter (1/3 size) in the $166-169 zone is defensible given oversold RSI (38), fundamental change signal of +6.4pp institutional ownership, and analyst target 29% higher. Invalidation is a daily close below $164 (recent low); below that, $155 is the next reference. Upside cap into earnings is $176-180 (gap-fill resistance). Do not chase the 1H forecast to $186 — 1D/1W model bands and macro breadth deterioration argue for a more muted bounce.
1-6 months: base case is that Q2 print reaffirms Enhertu strength and Zegfrovy accretion, and the stock mean-reverts toward the $185-195 zone as the Wainua overhang fades. Forward P/E 14.5x on $9.27 EPS supports a $180-200 fair range. Catalysts: July 27 earnings, Datroway TNBC regulatory updates, Zegfrovy integration commentary. What changes my mind: another late-stage trial miss, or guidance cut on 2026 top-line growth below high-single-digits.
1-3 years: AZN remains a top-tier oncology platform with Enhertu, Tagrisso, Imfinzi, and now Zegfrovy in NSCLC, plus Datroway and Truqap layering in. If the pipeline delivers on tumor-agnostic expansions and combination therapies, EPS can compound low-teens off the $9.27 2027 base toward $13+, supporting $220-260. Biggest structural risk is the 2027-2030 patent cliff on Tagrisso/Farxiga combined with $34B debt load — the balance sheet leaves less room to buy the way through a gap than peers.
Revenue is running $60.4B TTM with Q1 2026 revenue at $15.29B (+12.5% Y/Y) and gross margin holding above 82% at the segment level (74% reported). Operating margin of ~28% and ROE of 23.5% are best-in-class for large-cap pharma, with EPS TTM of $6.66 growing ~34% Y/Y and next-year consensus at $9.27 implying a forward P/E of 14.5x — a meaningful discount to the 25x trailing. Balance sheet is the soft spot: $34B total debt vs. $7.6B cash, D/E of 0.72, and negative working capital of -$2.96B; current ratio 0.91 and quick 0.71 show tight liquidity, though $14.2B TTM operating cash flow and $6.6B FCF comfortably service debt and the 1.9% dividend (47% payout). Capital allocation is tilted toward oncology M&A/licensing — the $600M upfront ($1.5B total) Dizal deal is a meaningful cash commitment but adds an already-commercialized EGFR asset. Nothing is broken; the market is simply repricing pipeline risk after the Wainua miss.
The multi-timeframe picture is decisively bearish near-term. On the 1D chart, price collapsed from ~$196 on July 1 to a $164 low, then bounced to $168.55 — a ~16% drawdown in two weeks. Price sits -7.3% below SMA20, -7.8% below SMA50, and -8.1% below SMA200, with RSI at 38.2 (oversold but not capitulation). The 1H forecast band projects a bounce to $186.85 (+11%), and the 4H band to $187.53, but the 1D and 1W bands are markedly less bullish ($172.88 and $133.80 respectively) — the model's own weekly bullish probability is 0.00, and 1wk directional accuracy only matches the naive baseline, so I discount the aggressive intraday bounce call. Key support is the $164 recent low and then the 52-week low $137.22; resistance stacks at $176 (prior consolidation), $184 (gap-down origin), and $196. The chart pattern is a clean breakdown with an oversold bounce attempt into overhead supply.
The dominant signal is mixed: the Wainua/eplontersen ATTR-CM Phase 3 setback (partnered with Ionis) is the proximate cause of the selloff and a real hit to a near-term diversification bet. Offsetting that, AZN announced the Dizal Zegfrovy licensing deal ($600M upfront, up to $1.5B) which adds a commercialized EGFR exon 20 NSCLC asset — a fast, tangible revenue lever for the oncology franchise. Seeking Alpha coverage frames the setup as Q2 preview with Enhertu momentum and EU approval as offsets, and a DCF-based note argues the stock may trade at a ~46% discount to intrinsic value post-selloff. Signal: oncology engine remains intact and is being reinforced; the setback is in a peripheral franchise. Noise: social sentiment is thin (only 4 tagged messages) and dominated by unrelated pumps. Analyst target of $216.99 (+29%) and Recom 1.63 (buy-side) are still constructive, but the July 27 earnings print is the near-term arbiter.
- Zegfrovy (sunvozertinib) global rights from Dizal — already US/China-approved for EGFR exon 20 NSCLC, immediate revenue addition, up to $1.5B in milestones
- Enhertu label expansion — Q2 preview coverage highlights EU approval and revenue surge as key print driver
- Datroway TNBC regulatory pathway in EU/global markets (per dossier watch item)
- Q1 2026 revenue +12.5% Y/Y to $15.29B — operational momentum still accelerating
- Institutional ownership stepped up +6.4pp to 62.2% over 45 days, indicating conviction accumulation on weakness
- July 27 earnings is a binary gap risk with IV crush — unfavorable guidance could send price to $155 test
- Wainua/eplontersen Phase 3 failure removes a diversification leg and dents the Ionis partnership narrative
- $34B total debt, D/E 0.72, negative working capital -$2.96B, current ratio 0.91 — limited flexibility for large M&A
- Chart broke SMA200 with -8.1% distance and -17.6% quarterly performance; macro breadth deteriorating (51.8% >200dMA)
- Tagrisso/Farxiga patent cliffs in the 2027-2030 window with generic/biosimilar pressure
- 1W forecast model shows $133.80 downside band — tail risk to $137 52-week low remains open if earnings disappoint
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord